In breast cancer, a drop in Ki-67 following short-term treatment with neoadjuvant chemotherapy predicts long-term response to that drug in the adjuvant setting.6 Our data suggest that Ki-67 could be used to stratify patients for entry into endometrial cancer adjuvant drug trials, excluding those whose prognosis is so good that they are unlikely to derive benefit from further therapeutic intervention beyond surgery. The gene discussed is MKI67; the disease is breast cancer.